Cargando…

Factors associated with physician-reported treatment status of patients with osteoarthritis pain

BACKGROUND: Osteoarthritis (OA) is typically associated with pain, but many patients are not treated. METHODS: This point in time study explored factors associated with treatment status, using logistic regression of data from the Adelphi OA Disease Specific Programme conducted in the United States....

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnitzer, Thomas J., Robinson, Rebecca L., Tive, Leslie, Cappelleri, Joseph C., Bushmakin, Andrew G., Jackson, James, Berry, Mia, Barlow, Sophie, Walker, Chloe, Viktrup, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134575/ https://www.ncbi.nlm.nih.gov/pubmed/35619074 http://dx.doi.org/10.1186/s12891-022-05414-6

Ejemplares similares

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons
por: Schnitzer, Thomas J., et al.
Publicado: (2023)

Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States
por: Robinson, Rebecca L., et al.
Publicado: (2022)

Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction
por: Schnitzer, Thomas J., et al.
Publicado: (2023)

Multimodal Treatment Patterns for Osteoarthritis and Their Relationship to Patient-Reported Pain Severity: A Cross-Sectional Survey in the United States
por: Nalamachu, Srinivas R, et al.
Publicado: (2020)

Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis
por: Garrison, Louis P., et al.
Publicado: (2021)

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”
por: Tive, Leslie A., et al.
Publicado: (2018)

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety
por: Schmelz, Martin, et al.
Publicado: (2019)

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials
por: Berenbaum, Francis, et al.
Publicado: (2021)

Nerve Growth Factor Signaling and Its Contribution to Pain
por: Barker, Philip A, et al.
Publicado: (2020)

Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countries
por: Perrot, Serge, et al.
Publicado: (2021)

Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity
por: Sadosky, Alesia B, et al.
Publicado: (2010)

Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip
por: Tive, Leslie, et al.
Publicado: (2019)

Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis
por: Walsh, David A., et al.
Publicado: (2022)

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab
por: Hunter, D.J., et al.
Publicado: (2022)

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis
por: Conaghan, Philip G., et al.
Publicado: (2022)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
por: Callis Duffin, Kristina, et al.
Publicado: (2019)

Examining the Relationships Among Treatment, Pain, and Physical Function in Patients With Osteoarthritis: A Mediation-Modeling Approach
por: Abraham, Lucy, et al.
Publicado: (2023)

Physician and patient perceptions of surgical procedures for osteoarthritis of the knee in the United States, Europe, and Japan: results of a real-world study
por: Fukui, N, et al.
Publicado: (2022)

General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo‐Controlled Trials
por: Berenbaum, Francis, et al.
Publicado: (2022)

Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis
por: Schnitzer, Thomas J., et al.
Publicado: (2021)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
por: Kristensen, Lars Erik, et al.
Publicado: (2023)

Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain
por: van Seventer, Robert, et al.
Publicado: (2011)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
por: Berenbaum, Francis, et al.
Publicado: (2021)

Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
por: Taylor, Peter C., et al.
Publicado: (2021)

Epidemiology of physician-diagnosed neuropathic pain in Brazil
por: Udall, Margarita, et al.
Publicado: (2019)

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
por: Panés, Julián, et al.
Publicado: (2015)

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
por: Markman, John D., et al.
Publicado: (2022)

Prognostics for pain in osteoarthritis: Do clinical measures predict pain after total joint replacement?
por: Barroso, Joana, et al.
Publicado: (2020)

Reorganization of functional brain network architecture in chronic osteoarthritis pain
por: Barroso, Joana, et al.
Publicado: (2020)

The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis
por: Shelbaya, Ahmed, et al.
Publicado: (2018)

Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis
por: Johnson, Courtney, et al.
Publicado: (2020)

Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis
por: Bennett, Robert M, et al.
Publicado: (2010)

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
por: de Vlam, Kurt, et al.
Publicado: (2022)

Characteristics of patients with neuropathic pain syndromes screened by the painDETECT questionnaire and diagnosed by physician exam
por: Kudel, Ian, et al.
Publicado: (2019)

The handling of urinary incontinence in Danish general practices after distribution of guidelines and voiding diary reimbursement: an observational study
por: Viktrup, Lars, et al.
Publicado: (2004)

A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis
por: Baliki, Marwan N, et al.
Publicado: (2008)

Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgia
por: Cappelleri, Joseph C, et al.
Publicado: (2009)

The association between lower back pain and health status, work productivity, and health care resource use in Japan
por: Sadosky, Alesia B, et al.
Publicado: (2015)

Measurement properties of painDETECT by average pain severity
por: Cappelleri, Joseph C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_marujsf6eosim9deinp6mskrbu